Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Altimmune › CFO exercised or converted 19K ALT derivative securities
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 11, 2026
Reporting period Not applicable
Filed with the SEC Nov 13, 2026 CFO Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001251779-26-000015
Filed / recorded
Nov 13, 2026, 9:05 PM UTC
Added to OQRO Nov 13, 2026, 9:06 PM UTC
Data quality Verified: identifiers matched exactly
Reporting person Gregory L Weaver
Officer title Chief Financial Officer
Security Common Stock, par value $0.0001
Table Non-derivative (Table I)
Transaction date Nov 11, 2026
Acquired / disposed Acquired (A)
Footnotes from the filing Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
Around the same time Insider buying
3 insiders in a week, 6th time since 2007 Traded Nov 13 · filed the same day
The CEO of Altimmune paid $50K out of pocket for Altimmune shares. 2 other people at Altimmune bought some too, in the same month. It was the first purchase in over a year.
Insider filing
Traded Nov 11 · filed 2 days later
Routine share withholding; mechanical by default.
Insider filing
Traded Nov 11 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Sep 24, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.” Oct 23, 2026 Company filing · Form 8-K · Executive change, Reg FD Changed a top executive or board member, and shared information with investors Oct 27, 2026 Company filing · Form 8-K · New debt Took on new debt or obligations Nov 10, 2026 5% stake STATE STREET CORPORATION reported a passive stake (13G) of 4.3% What came next Nov 12, 2026 Company filing · Form 8-K · Results Reported its results Nov 13, 2026 Insider · 3 people Insiders: 3 purchases (~$82K) 